Holen Sie sich die Stockscreener-App
1.39
6.51%
0.085
Schlusskurs vom Vortag:
$1.305
Offen:
$1.27
24-Stunden-Volumen:
68,768
Relative Volume:
0.02
Marktkapitalisierung:
$6.23M
Einnahmen:
$72,100
Nettoeinkommen (Verlust:
$-3.60M
KGV:
-1.1681
EPS:
-1.19
Netto-Cashflow:
$-3.37M
1W Leistung:
-0.71%
1M Leistung:
-29.44%
6M Leistung:
-4.14%
1J Leistung:
-11.46%
1-Tages-Spanne:
$1.24
$1.40
1-Wochen-Bereich:
$1.20
$1.5195
52-Wochen-Spanne:
$0.77
$4.50
Silo Pharma Inc Stock (SILO) Company Profile
Firmenname
Silo Pharma Inc
Sektor
Branche
Telefon
(718) 400-9031
Adresse
677 N. WASHINGTON BLVD, SARASOTA
Vergleichen Sie SILO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SILO
SILO PHARMA INC
|
1.71 | 17.96M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1935 | 408.35M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
20.50 | 372.90M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
0.4399 | 278.60M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.79 | 120.14M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
4.0439 | 52.60M | 0 | 0 | 0 | 0.00 |
Silo Pharma Inc Aktie (SILO) Neueste Nachrichten
Silo Files Provisional Patent For SPC-15 Combination Treatment To Target Stress-Induced Disorders - Nasdaq
Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment - The Manila Times
Silo Pharma Expands Intellectual Property Portfolio with - GlobeNewswire
Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for ... - The Bakersfield Californian
Revolutionary Mental Health Treatment Patent: Silo Pharma's Dual-Action SPC-15 Shows Promising Results - StockTitan
Silo Pharma reports positive early data on pain treatment implant By Investing.com - Investing.com Nigeria
Silo Pharma Announces Positive Initial Pharmacokinetic, - GlobeNewswire
Silo Pharma reports positive early data on pain treatment implant - Investing.com
SILO’s valuation metrics: A comprehensive analysis - US Post News
Silo Pharma's SP-26 Shows Promising Initial Safety And Absorption Data For Pain Relief - Nasdaq
Silo Pharma Reports Positive Safety Update from SP-26 Ketamine Implant Study with No Serious Side Effects Observed - Nasdaq
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 - The Bakersfield Californian
Revolutionary Pain Treatment: SILO's Ketamine Implant Aces Initial Safety Tests - StockTitan
Monitoring SILO Pharma Inc (SILO) after recent insider movements - Knox Daily
SILO Pharma Inc (SILO) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
SILO Pharma Inc’s Market Journey: Closing Strong at 1.79, Up 11.18 - The Dwinnex
Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment - GlobeNewswire
Silo Pharma files provisional patent for PTSD treatment - MSN
Silo Pharma Files Breakthrough PTSD Treatment Patent, Expands Columbia Tech Portfolio - StockTitan
Looking For A Good Stock? Let This SILO Pharma Inc (NASDAQ: SILO) Analysis Help. - Stocks Register
After A Patent Win, Analysts Think This Penny Stock Can Gain 465% In 2025 - Barchart
Why Zoomcar Shares Are Trading Higher By Over 40%; Here Are 20 Stocks Moving Premarket - Benzinga
Silo Pharma awarded U.S. patent for PTSD treatment - Yahoo Finance
Silo Pharma secures patent for PTSD intranasal treatment By Investing.com - Investing.com Nigeria
SILO Pharma flies high on impending patent for intranasal PTSD drug - Mugglehead
Crude Oil Down 1%; US Weekly Jobless Claims Decline - Benzinga
Silo Pharma shares soar on patent allowance news By Investing.com - Investing.com South Africa
Silo Pharma shares soar on patent allowance news - Investing.com India
Silo Pharma secures patent for PTSD intranasal treatment - Investing.com
Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial - The Manila Times
Silo Pharma Secures Key Patent Protection for PTSD Treatment SPC-15, Strengthens IP Portfolio - StockTitan
Silo Pharma progresses with PTSD and pain treatments - Investing.com
Silo Pharma Issues Letter to Shareholders Detailing - GlobeNewswire
Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain - Yahoo Finance UK
Silo Pharma Advances PTSD Drug SPC-15 Toward Clinical Trials, Plans 2025 IND Filing - StockTitan
Silo Pharma initiates pharmacokinetic, tolerability study for SP-26 - Yahoo Finance
Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia - The Manila Times
Silo Pharma Initiates Pharmacokinetic and Tolerability Study for Sp-26 Targeting Chronic Pain and Fibromyalgia - Marketscreener.com
Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain - The Bakersfield Californian
Pre-market Movers: PALI, KROS, AVGR, TRVI... - RTTNews
Silo Pharma partners with Kymanox to develop ketamine implant - MSN
Why Is Silo Pharma Stock Gaining Today? - Benzinga
Silo Pharma advances ketamine implant for chronic pain By Investing.com - Investing.com UK
Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management - GlobeNewswire
Silo Pharma Partners with Kymanox to Develop Novel Ketamine Implant Device | SILO Stock News - StockTitan
Silo Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Silo Pharma stock hits 52-week low at $0.83 amid market challenges - Investing.com Canada
Silo Pharma stock hits 52-week low at $0.83 amid market challenges By Investing.com - Investing.com South Africa
Silo Pharma CEO Eric Weisblum buys $4,625 in company stock - Investing.com
Silo Pharma CEO Eric Weisblum buys $4,625 in company stock By Investing.com - Investing.com Canada
Finanzdaten der Silo Pharma Inc-Aktie (SILO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.53%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):